Media365
“Biotechnology is a high-risk field like a ‘molecular casino’,” said founder Alex Zhavoronkov. “Even with artificial intelligence, you can lose 90 per cent of the time.”
The 11-year-old company was training and testing an AI-powered drug-discovery tool, Pharma.AI, to “enable faster, cheaper and more successful drug discovery with higher novelty and confidence”, he said. Zhavoronkov likened it to an “Einstein” capable of mastering fields from mathematics and physics to chemistry, biology and writing, pushing drug discovery to “new frontiers”.
The company’s proprietary generative AI platform could read and interpret genomics and other biological data to create new drug molecule structures from scratch, instead of screening existing chemical libraries, according to Zhavoronkov.
